Publications (66) KARIM BENABDELLAH EL KHLANJI publications

filter_list

2025

  1. Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group

    Molecular Therapy Nucleic Acids, Vol. 36, Núm. 1

  2. An Overview and Comparative Analysis of CRISPR-SpCas9 gRNA Activity Prediction Tools

    CRISPR Journal, Vol. 8, Núm. 2, pp. 89-104

  3. HLA molecules: Another challenge for CAR T cell therapy

    Current Research in Translational Medicine, Vol. 73, Núm. 4

  4. Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges

    Molecular Therapy Nucleic Acids, Vol. 36, Núm. 3

  5. Trajectory of genome editing technology

    BMC Biology

2024

  1. Application of Genomic Medicine in Africa: 14th Conference of the African Society of Human Genetics and the 2nd International Congress of the Moroccan Society of Genomics and Human Genetics, Rabat, Morocco 2022

    American Journal of Tropical Medicine and Hygiene, Vol. 110, Núm. 6, pp. 1279-1284

  2. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy

    Molecular Cancer, Vol. 23, Núm. 1

  3. Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome

    Frontiers in Immunology, Vol. 15

2023

  1. CRISPR delivery with extracellular vesicles: Promises and challenges

    Journal of Extracellular Biology, Vol. 2, Núm. 9

  2. Estradiol and Estrone Have Different Biological Functions to Induce NF-κB-Driven Inflammation, EMT and Stemness in ER+ Cancer Cells

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  3. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL

    Frontiers in immunology, Vol. 14, pp. 1165870

  4. High-Density Lipoprotein in Metabolic Disorders and Beyond: An Exciting New World Full of Challenges and Opportunities

    Pharmaceuticals, Vol. 16, Núm. 6

  5. Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 322-339

  6. Preclinical Evidence for the Use of Oral Mesenchymal Stem Cell-Derived Extracellular Vesicles in Bone Regenerative Therapy: A Systematic Review

    Stem Cells Translational Medicine, Vol. 12, Núm. 12, pp. 791-800

  7. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi

    Molecular Therapy Nucleic Acids, Vol. 34

  8. The Black Hole: CAR T Cell Therapy in AML

    Cancers, Vol. 15, Núm. 10

2022

  1. Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

    Frontiers in Immunology, Vol. 13

  2. Erratum: Physiological lentiviral vectors for the generation of improved CAR-T cells (Molecular Therapy - Oncolytics (2022) 25 (335–349), (S2372770522000687), (10.1016/j.omto.2022.05.003))

    Molecular Therapy - Oncolytics

  3. Genetic engineering of autologous or allogeneic immune effector cells

    The EBMT/EHA CAR-T Cell Handbook (Springer International Publishing), pp. 7-10

  4. Physiological lentiviral vectors for the generation of improved CAR-T cells

    Molecular Therapy - Oncolytics, Vol. 25, pp. 335-349